Date Time Share Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who are at risk for pregnancy.